Leuprolide Acetate Market Research Report - Forecast to 2023

Leuprolide Acetate Market Research Report, by Application (Prostate Cancer, Precocious, and Uterine Fibroid), by Mode of Administration (Intramuscular, Subcutaneous), by End-User (Hospitals, Clinics, Medical Institutes)- Forecast Till 2027

ID: MRFR/Pharma/0301-HCR | August 2022 | Region: Global | 122 Pages         

[{"chapter_no"=>"1", "title"=>"Report Prologue", "enterprise_usd"=>1350, "description"=>nil}, {"chapter_no"=>"2", "title"=>"Market Introduction", "enterprise_usd"=>0, "description"=>"2.1 Definition \n2.2 Scope of the Study \n2.2.1 Research Objective \n2.2.2 Assumptions \n2.2.3 Limitations\n"}, {"chapter_no"=>"3", "title"=>"Research Methodology", "enterprise_usd"=>0, "description"=>"3.1 Introduction\n3.2 Primary Research \n3.3 Secondary research \n3.4 Market Size Estimation\n"}, {"chapter_no"=>"4", "title"=>"Market Dynamics", "enterprise_usd"=>950, "description"=>"4.1 Drivers \n4.2 Restraints\n4.3 Opportunities \n4.4 Challenges\n4.5 Macroeconomic Indicators\n4.6 Technology Trends & Assessment\n"}, {"chapter_no"=>"5", "title"=>"Market Factor Analysis", "enterprise_usd"=>950, "description"=>"5.1 Porter’s Five Forces Analysis\n5.1.1 Bargaining Power of Suppliers \n5.1.2 Bargaining Power of Buyers\n5.1.3 Threat of New Entrants \n5.1.4 Threat of Substitutes \n5.1.5 Intensity of Rivalry \n5.2 Value Chain Analysis\n5.3 Investment Feasibility Analysis \n5.4 Pricing Analysis\n"}, {"chapter_no"=>"6", "title"=>"Global Leuprolide Acetate Market, by Application", "enterprise_usd"=>1650, "description"=>"6.1 Introduction\n6.2 Prostate Cancer\nMarket Estimates & Forecast, 2017–2023\n6.3 Precocious\nMarket Estimates & Forecast, 2017–2023\n6.4 Uterine Fibroid\nMarket Estimates & Forecast, 2017–2023\n6.5 Others\n"}, {"chapter_no"=>"7", "title"=>"Global Leuprolide Acetate Market, by Mode of Administration ", "enterprise_usd"=>1650, "description"=>"7.1 Introduction\n7.2 Intramuscular\nMarket Estimates & Forecast, 2017–2023\n\n7.3 Subcutaneous\nMarket Estimates & Forecast, 2017–2023\n"}, {"chapter_no"=>"8", "title"=>"Global Leuprolide Acetate Market, by End-User", "enterprise_usd"=>1650, "description"=>"8.1 Introduction\n8.2 Hospitals\nMarket Estimates & Forecast, 2017–2023\n8.3 Clinics\nMarket Estimates & Forecast, 2017–2023\n8.4 Medical Institutes\nMarket Estimates & Forecast, 2017–2023\n8.4 Others\n"}, {"chapter_no"=>"9", "title"=>"Global Leuprolide Acetate Market, by Region", "enterprise_usd"=>1650, "description"=>"9.1 Introduction\n9.2 The Americas\n9.2.1 North America\n9.2.1.1 U.S.\n9.2.1.1 Canada\n9.2.2 South America\n9.3 Europe\n9.3.1 Western Europe\n9.3.1.1 Germany\n9.3.1.2 France\n9.3.1.3 Italy\n9.3.1.4 Spain\n9.3.1.5 U.K.\n9.3.1.6 Rest of Western Europe\n9.3.2 Eastern Europe\n9.4 Asia Pacific\n9.4.1 Japan\n9.4.2 China\n9.4.3 India\n9.4.4 Australia\n9.4.5 Republic of Korea\n9.4.6 Rest of Asia Pacific\n9.5 The Middle East & Africa\n9.5.1 United Arab Emirates\n9.5.2 Saudi Arabia\n9.5.3 Oman\n9.5.4 Kuwait\n9.5.5 Qatar\n9.5.6 Rest of the Middle East & Africa\n"}, {"chapter_no"=>"10", "title"=>"Company Landscape", "enterprise_usd"=>1050, "description"=>"10.1 Introduction \n10.2 Market Share Analysis \n10.3 Key Development & Strategies \n10.3.1 Key Developments\n"}, {"chapter_no"=>"11", "title"=>"Company Profiles", "enterprise_usd"=>900, "description"=>"11.1 TOLMAR Pharmaceuticals, Inc.\n11.1.1 Company Overview \n11.1.2 Product Overview \n11.1.3 Financials \n11.1.4 Key Developments\n11.1.5 SWOT Analysis \n11.2 Varian Pharmed \n11.2.1 Company Overview \n11.2.2 Product Overview \n11.2.3 Financial Overview \n11.2.4 Key Developments \n11.2.5 SWOT Analysis \n11.3 avenit AG\n11.3.1 Company Overview \n11.3.2 Product Overview \n11.3.3 Financial Overview\n11.3.4 Key Development \n11.3.5 SWOT Analysis \n11.4 Takeda Pharmaceutical Company Limited\n11.4.1 Company Overview \n11.4.2 Product/Business Segment Overview \n11.4.3 Financial Overview \n11.4.4 Key Development \n11.4.5 SWOT Analysis \n11.5 Sun Pharmaceutical Industries Ltd.\n11.5.1 Company Overview \n11.5.2 Product Overview \n11.5.3 Financial overview \n11.5.4 Key Developments\n11.5.5 SWOT Analysis \n11.6 Livzon Pharmaceutical Group Co., Ltd. \n11.6.1 Company Overview \n11.6.2 Product Overview \n11.6.3 Financial Overview \n11.6.4 Key Developments \n11.6.5 SWOT Analysis\n11.7 Beijing Biote Pharmaceutical Co., Ltd\n11.7.1 Overview \n11.7.2 Product Overview \n11.7.3 Financials \n11.7.4 Key Developments \n11.7.5 SWOT Analysis \n11.8 Soho-YImIng\n11.8.1 Company Overview \n11.8.2 Product/Business Segment Overview \n11.8.3 Financial Overview \n11.8.4 Key Development \n11.8.5 SWOT Analysis \n11.9 AbbVie Inc. \n11.9.1 Company Overview \n11.9.2 Product Overview \n11.9.3 Financial overview \n11.9.4 Key Developments \n11.9.5 SWOT Analysis\n11.10 Sanofi \n11.10.1 Company Overview \n11.10.2 Product Overview \n11.10.3 Financial overview \n11.10.4 Key Developments\n11.10.5 SWOT Analysis\n11.11 Astellas Pharma\n11.11.1 Company Overview \n11.11.2 Product Overview \n11.11.3 Financial overview \n11.11.4 Key Developments\n11.11.5 SWOT Analysis\n11.12 Abbott\n11.12.1 Company Overview \n11.12.2 Product Overview \n11.12.3 Financial overview \n11.12.4 Key Developments\n11.12.5 SWOT Analysis\n11.13 Merck KGaA\n11.13.1 Company Overview \n11.13.2 Product Overview \n11.13.3 Financial overview \n11.13.4 Key Developments\n11.13.5 SWOT Analysis\n11.14 Pfizer Inc. \n11.14.1 Company Overview \n11.14.2 Product Overview \n11.14.3 Financial overview \n11.14.4 Key Developments\n11.14.5 SWOT Analysis\n11.15 Others\n"}, {"chapter_no"=>"12", "title"=>"MRFR Conclusion", "enterprise_usd"=>750, "description"=>"Chapter 12 MRFR Conclusion \n12.1 Key Findings \n12.1.1 From CEO’s View Point \n12.1.2 Unmet Needs of the Market \n12.2 Key Companies to Watch \n12.3 Prediction of the Pharmaceutical Industry\n"}, {"chapter_no"=>"13", "title"=>"Appendix", "enterprise_usd"=>0, "description"=>"13.1 References 119"}, {"chapter_no"=>"14", "title"=>"List of Tables", "enterprise_usd"=>nil, "description"=>"Table 1 Leuprolide Acetate Industry Synopsis, 2017–2023\nTable 2 Leuprolide Acetate Market Estimates & Forecast, 2017–2023, (USD Million)\nTable 3 Leuprolide Acetate Market, by Region, 2017–2023, (USD Million)\nTable 4 Leuprolide Acetate Market, by Application, 2017–2023, (USD Million)\nTable 5 Leuprolide Acetate Market, by Mode of Administration, 2017–2023, (USD Million)\nTable 6 Leuprolide Acetate Market, by End-User, 2017–2023, (USD Million)\nTable 7 North America Leuprolide Acetate Market, by Application, 2017–2023, (USD Million)\nTable 8 North America Leuprolide Acetate Market, by Mode of Administration, 2017–2023, (USD Million)\nTable 9 North America Leuprolide Acetate Market, by End-User, 2017–2023, (USD Million)\nTable 10 U.S. Leuprolide Acetate Market, by Application, 2017–2023, (USD Million)\nTable 11 U.S. Leuprolide Acetate Market, by Mode of Administration, 2017–2023, (USD Million)\nTable 12 U.S. Leuprolide Acetate Market, by End-User, 2017–2023, (USD Million)\nTable 13 Canada Leuprolide Acetate Market, by Application, 2017–2023, (USD Million)\nTable 14 Canada Leuprolide Acetate Market, by Mode of Administration, 2017–2023, (USD Million)\nTable 15 Canada Leuprolide Acetate Market, by End-User, 2017–2023, (USD Million)\nTable 16 South America Leuprolide Acetate Market, by Application, 2017–2023, (USD Million)\nTable 17 South America Leuprolide Acetate Market, by Mode of Administration, 2017–2023, (USD Million)\nTable 18 South America Leuprolide Acetate Market, by End-User, 2017–2023, (USD Million)\nTable 19 Europe Leuprolide Acetate Market, by Application, 2017–2023, (USD Million)\nTable 20 Europe Leuprolide Acetate Market, by Mode of Administration, 2017–2023, (USD Million)\nTable 21 Europe Leuprolide Acetate Market, by End-User, 2017–2023, (USD Million)\nTable 22 Western Europe Leuprolide Acetate Market, by Application, 2017–2023, (USD Million)\nTable 23 Western Europe Leuprolide Acetate Market, by Mode of Administration, 2017–2023, (USD Million)\nTable 24 Western Europe Leuprolide Acetate Market, by End-User, 2017–2023, (USD Million)\nTable 25 Eastern Europe Leuprolide Acetate Market, by Application, 2017–2023, (USD Million)\nTable 26 Eastern Europe Leuprolide Acetate Market, by Mode of Administration, 2017–2023, (USD Million)\nTable 27 Eastern Europe Leuprolide Acetate Market, by End-User, 2017–2023, (USD Million)\nTable 28 Asia Pacific Leuprolide Acetate Market, by Application, 2017–2023, (USD Million)\nTable 29 Asia Pacific Leuprolide Acetate Market, by Mode of Administration, 2017–2023, (USD Million)\nTable 30 Asia Pacific Leuprolide Acetate Market, by End-User, 2017–2023, (USD Million)\nTable 31 The Middle East & Africa Leuprolide Acetate Market, by Application, 2017–2023, (USD Million)\nTable 32 The Middle East & Africa Leuprolide Acetate Market, by Mode of Administration, 2017–2023, (USD Million)\nTable 33 The Middle East & Africa Leuprolide Acetate Market, by End-User, 2017–2023, (USD Million)\n"}, {"chapter_no"=>"15", "title"=>"List of Figures", "enterprise_usd"=>nil, "description"=>"Figure 1 Research Process\nFigure 2 Segmentation for Leuprolide Acetate Market\nFigure 3 Segmentation Market Dynamics for Leuprolide Acetate Market\nFigure 4 Global Leuprolide Acetate Market Share, by Application 2016\nFigure 5 Global Leuprolide Acetate Market Share, by Mode of Administration 2016\nFigure 6 Global Leuprolide Acetate Market Share, by End-User, 2016\nFigure 7 Global Leuprolide Acetate Market Share, by Region, 2016\nFigure 8 North America Leuprolide Acetate Market Share, by Country, 2016\nFigure 9 Europe Leuprolide Acetate Market Share, by Country, 2016\nFigure 10 Asia Pacific Leuprolide Acetate Market Share, by Country, 2016\nFigure 11 The Middle East & Africa Leuprolide Acetate Market Share, by Country, 2016\nFigure 12 Global Leuprolide Acetate Market: Company Share Analysis, 2016 (%)\nFigure 13 TOLMAR Pharmaceuticals, Inc.: Key Financials\nFigure 14 TOLMAR Pharmaceuticals, Inc.: Segmental Revenue\nFigure 15 TOLMAR Pharmaceuticals, Inc.: Geographical Revenue\nFigure 16 Varian Pharmed: Key Financials\nFigure 17 Varian Pharmed: Segmental Revenue\nFigure 18 Varian Pharmed: Geographical Revenue\nFigure 19 avenit AG: Key Financials\nFigure 20 avenit AG: Segmental Revenue\nFigure 21 avenit AG: Geographical Revenue\nFigure 22 Takeda Pharmaceutical Company Limited: Key Financials\nFigure 23 Takeda Pharmaceutical Company Limited: Segmental Revenue\nFigure 24 Takeda Pharmaceutical Company Limited: Geographical Revenue\nFigure 25 Sun Pharmaceutical Industries Ltd.: Key Financials\nFigure 26 Sun Pharmaceutical Industries Ltd.: Segmental Revenue\nFigure 27 Sun Pharmaceutical Industries Ltd.: Geographical Revenue\nFigure 28 Livzon Pharmaceutical Group Co., Ltd.: Key Financials\nFigure 29 Livzon Pharmaceutical Group Co., Ltd.: Segmental Revenue\nFigure 30 Livzon Pharmaceutical Group Co., Ltd.: Geographical Revenue\nFigure 31 Beijing Biote Pharmaceutical Co., Ltd: Key Financials\nFigure 32 Beijing Biote Pharmaceutical Co., Ltd: Segmental Revenue\nFigure 33 Beijing Biote Pharmaceutical Co., Ltd: Geographical Revenue\nFigure 34 Soho-YImIng: Key Financials\nFigure 35 Soho-YImIng: Segmental Revenue\nFigure 36 Soho-YImIng: Geographical Revenue\nFigure 37 AbbVie Inc.: Key Financials\nFigure 38 AbbVie Inc.: Segmental Revenue\nFigure 39 AbbVie Inc.: Geographical Revenue\nFigure 40 Sanofi: Key Financials\nFigure 41 Sanofi: Segmental Revenue\nFigure 42 Sanofi: Geographical Revenue\nFigure 43 Astellas Pharma: Key Financials\nFigure 44 Astellas Pharma: Segmental Revenue\nFigure 45 Astellas Pharma: Geographical Revenue\nFigure 46 Abbott: Key Financials\nFigure 47 Abbott: Segmental Revenue\nFigure 48 Abbott: Geographical Revenue\nFigure 49 Merck KGaA: Key Financials\nFigure 50 Merck KGaA: Segmental Revenue\nFigure 51 Merck KGaA: Geographical Revenue\nFigure 52 Pfizer Inc.: Key Financials\nFigure 53 Pfizer Inc.: Segmental Revenue\nFigure 54 Pfizer Inc.: Geographical Revenue\n"}]

Leuprolide Acetate Market Speak to Analyst Request a Free Sample

Leuprolide Acetate Market Overview


It has been estimated that the leuprolide acetate market holds a CAGR value of about 5.4% during the forecast period. From the market analysis, it has been found that leuprolide is very much similar to the gonadotropin-releasing hormone. Leuprolide has been marked to be a nonapeptide acetate salt which has a therapeutic effect. It can easily hold the receptors of the gonadotropin hormone. This salt has a therapeutic effect that helps in treating prostate cancer in males and the uterine fibroids of females. During the year 2015, the World Cancer Research Fund International Organization marked a sudden rise in 1.1 million prostate cancer cases.


It too ranged in rising of 8% of the new cancer cases. From the leuprolide acetate market analysis it has been found that the BMC Women’s Health Journal reported about the rise in cases of females suffering from uterine fibroids which ranged from 4.5% in the region of the United Kingdom to 9.8% in the region of Italy. As per the Population Reference Bureau in the year 2016, the region of the United States experienced huge growth in the geriatric population which was estimated to be double and was about to reach 98 million by the end of the forecast period of 2026. The market is growing at a steady exponential rate along with the increase in adoption of new market players is expected to grow above the market horizon.


Leuprolide Acetate Market COVID 19 Analysis


From a global and regional perspective, it has been found that COVID 19 has affected the whole of the countrywide population. COVID also affected both the production and consumption ends. It also affected the new market trends. Moreover, the pandemic affected the recent development and the strategies which helped in dealing with the COVID. Moreover, COVID affected the demand of the products whereas it started affecting the value chain analysis and disrupted the market scenario. It affected the financial conditions of the industry. After analyzing the present situation of COVID the market generated some of the recovery factors against the crisis.


Leuprolide Acetate Market Dynamics


Drivers- prevalent in the conditions of prostate cancer and the uterine fibroid are some of the major driving forces of the leuprolide acetate market growth during the leuprolide acetate market forecast period. The engrossment of the old-age population and the rise in growth in pharma and healthcare units have helped in driving up the market size.


Opportunities- the increase in the adoption of hormonal therapies for the treatment of uterine fibroids and prostate cancer raises the opportunity of the market size. It has been marketed from the leuprolide acetate market outlook that endometriosis experienced by the population helps in uprising market size and its growth. Besides it, the market vendors should majorly focus on adopting faster segments for improving the market size.


Challenges- giving much more priority to surgery deteriorates the market growth.


Restraints- some of the disadvantages or the side effects associated with this salt are upset stomach, swelling u[p of the breast, bleeding from the vagina, impotence as some of the restraining factors of the expansion of the leuprolide acetate market size. Some of the factors besides it like the fewer capita expenses of the healthcare units, strict rules and regulations of the government along with the presence of some of the alternative treating methods in the acetate industry are the major restraining forces of the leuprolide acetate market size as per the market outlook during the forecast period of market growth.


Leuprolide Acetate Market Segmentation


Globally, it has been found that the market is being classified as per the application, mode of administration, and the end-users.


As per the application, the leuprolide acetate industry is being classified into prostate cancer, fibroid of uterine in females, precocious, and many others.


As per the administration, the industry is being divided into intramuscular and subcutaneous. As per the end-user segment, the industry is being classified into hospital units, medicals, clinics, and many more.


Based on end-users the market is being divided into medicals, clinics, research fields, and some academic institutions. As per the geographical analysis, it was found that the market is being classified into some of the European region, the Asian region, North American areas, and some areas of the rest of the world.


The technology adopted by some of the companies includes a major focus on research activities. Adopting technology as per the new leuprolide acetate market trends gives huge insights which help in the growth and development of the business. Moreover, technology also helped the market players to occupy an optimization position in the market.


Figure 1- Leuprolide Acetate Global Market Share, by Region


 Leuprolide Acetate Market Share


Sources: World Cancer Research Fund International, BMC Women's Health, Population Reference Bureau, Cancer Research UK, annual reports, press release, white paper, and company presentation


Leuprolide Acetate Market Regional Analysis


The region of the United States covers a major leuprolide acetate market share. The rise in prevalence of prostate cancer cases among males and uterine cases in the case of females has helped in driving up the market growth. The rise in the size of the healthcare units has helped in driving up the market size. During the leuprolide acetate market forecast period it has also been marked that the European region in the global market has contributed to the rise in population rate along with the availability of capital for both research and developmental activities due to which the demand in this region has increased. Economically forward companies in the regions of the United States, the United Kingdom, Italy, France, and many others have shown a great rise in rate. As per the Cancer Research in the United Kingdom region, it was reported that a rise in 47,151 new prostate cases in the year 2015 was marked. Besides it, the death rate was also marked, accounting for 11,287 in the same year of 2015.


Leuprolide Acetate Market Competitive Landscape


From the leuprolide acetate market analysis of the driving factors and the challenging factors assists in deduction of the goals and helps in purifying the marketing strategies which helps in attaining the competitive spirit in the market. Some of the competitors of the market region include COLMAR Pharmaceuticals, Pfizer Inc. of the United States, Varian Pharmed of Iran, Merck kGaA of Germany, Avent AG of Switzerland, Abbot Of the United States, Takeda Pharmaceuticals Company ltd of the Japan region, Astellas Pharma of Japan, Sun Pharmaceuticals Industries ltd of Indian region, Sanofi of France, Livzon Pharma Group Co. ltd of Chinese region, AbbVie Inc. of the United States region, Beijing Biota Pharmaceuticals Co. ltd of Chinese region Soho-Filming of the Chinese region and many more. Moreover, the growth rate in the market is concentrated whereas the vendors are carrying out both organic and inorganic growth strategies to compete in the global market. The company profiles include the sustainability towards production units and the rise in prospectus rate of the leading competitors.


Leuprolide Acetate Market Report Overview


From the leuprolide acetate market analysis it has been found that the report gives detailed and further information regarding the new and upcoming leuprolide acetate market trends that will have a great effect on the market size and market growth. The industry gives in-depth insights and in-depth analysis about the company vendors. The report gives a comprehensive analysis of the competitive sectors and the market performance of the market. The report also gives in-depth ideas about the new growth strategies, launching of new products, investment, and the new leuprolide acetate market share. It gives a good comprehensive coverage about the new marketing positions which helps in accessing their positions within the market. The report gives a detailed picture of the study, their synthesis and gives a good market analysis about the major parameters. The report also analyzes the uprising of new marketing trends and the new challenging factors that play a great role in market growth.



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2017-2023: 5.4%
  Base Year   2018
  Forecast Period   2027
  Historical Data   2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors and Trends
  Segments Covered   Application, mode of administration, and end-user
  Geographies Covered   North America, Europe, Asia-Pacific and Rest of the World (RoW)
  Key Vendors   Varian Pharmed (Iran), avenit AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), Livzon Pharmaceutical Group Co., Ltd. (China), Beijing Biote Pharmaceutical Co., Ltd (China), Soho-YImIng (China), AbbVie Inc. (U.S.), Sanofi (France), Astellas Pharma (Japan), Abbott (U.S), Merck KGaA (Germany), Pfizer Inc. (U.S.)
  Key Market Opportunities   Research and Development Activity
  Key Market Drivers

  • Upset stomach
  • Breast swelling
  • Vaginal bleeding
  • Impotence
  • Increasing prevalence of prostate cancer and the uterine fibroid


  • Speak to Analyst Ask for Customization